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ABSTRACT
We clarified the clinical prevalence of ovarian metastases from colorectal cancers 
(CRCs) in 296 female patients with CRC and evaluated clinical outcomes with relation 
to their mutational profiles, such as BRAF/KRAS mutation and microsatellite instability 
(MSI) status. The female CRCs were categorised into three subsets: CRCs with ovarian 
metastases [6.4% (n = 19), 5-year overall survival (OS) = 24.7%], CRCs with extra-
ovarian metastases only [32.4% (n = 96), 5-year OS = 34.5%] and CRCs without any 
recurrence or metastasis [61.2% (n = 181), 5-year OS = 91.3%]. All patients with 
ovarian metastases underwent oophorectomy; of these, 9 who received preoperative 
chemotherapy had measurable metastases to extra-ovarian sites and the ovaries. 
Although 5 of 9 (56%) achieved partial response or complete response at extra-
ovarian sites, no patient archived objective response at ovarian sites. Regarding the 
mutation profiles, in CRCs with extra-ovarian metastases only, the median survival time 
(MST) after initial treatments to progression to stage IV or recurrence was 13 [95% 
confidence interval (CI): 7–16 months] in BRAF-mutant and 34 months (95% CI: 22–58 
months) in BRAF wild-type (P = 0.0033). Although ovarian metastases demonstrated 
poor response to systemic chemotherapy in CRCs with ovarian metastases, the MST 
after initial treatments to progression to stage IV or recurrence was 22 (95% CI: 21–25 
months) in BRAF-mutant and 38 months (95% CI: 24–42 months) in BRAF wild-type 
(P = 0.0398). The outcomes of patients with ovarian metastases could be improved by 
oophorectomy regardless of their mutation profiles.
INTRODUCTION
Ovarian metastasis is estimated to account for 5%–
30% of all ovarian malignancies [1–5] and most frequently 
originates from colorectal cancers (CRC), followed by 
cancers of the endometrium, stomach, appendix and breast 
[6]. Although 12.5%–49% of metastatic ovarian cancers 
originate from CRCs, the ovary is an uncommon site for 
metastasis from advanced CRCs. In fact, synchronous 
and metachronous ovarian metastases were reported 
in approximately 9% and 7% of women with CRCs, 
respectively [7–11].
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In the past decade, remarkable progress has 
been achieved in the treatment of advanced CRC, 
particularly after the introduction of effective systemic 
chemotherapeutic regimens, including oxaliplatin and 
irinotecan, and molecular-targeted antibodies [12]. These 
novel agents have enabled better tumour response rates 
and overall survivals (OS) in patients. However, despite 
these significant improvements, patients with ovarian 
metastases from CRCs have a worse prognosis than 
patients with CRCs that metastasised to other sites [13].
It remains unknown whether the adverse 
prognosis of ovarian metastases relative to the 
metastases to other sites reflects a more advanced stage 
of the disease, intrinsic aggressiveness of the disease, 
or reduced sensitivity to systemic chemotherapy [14]. A 
recent study on patients with CRCs demonstrated that 
the responses to chemotherapy were less favourable 
in those with ovarian metastases than in those with 
extra-ovarian metastases [13]. Another study reported 
that the tumour response rate after fluorouracil-based 
chemotherapy was 40% in patients with extra-ovarian 
metastases and only 5% in those with ovarian metastases 
[14]. The absence of objective tumour responses in 22 
patients with CRCs who had ovarian metastases and 
the tumour control rate of 65% in patients with extra-
ovarian metastatic lesions supported these earlier 
results [13]. Lee et al. reported that patients with CRCs 
who underwent oophorectomy or metastatectomy for 
ovarian metastases before undergoing chemotherapy 
survived significantly longer than those who did not 
undergo oophorectomy (28.1 vs. 21.2 months) [15]. In 
the multivariate analysis, the absence of oophorectomy 
was an independent prognostic factor for worse 
survival and had a relative risk of 1.954. In summary, 
the resection of ovarian metastases seemed to confer 
survival benefits on CRC patients.
Recently, treatment strategies for advanced 
CRC have leaned towards mutation profile-based 
precision medicine; in other words, the mutational 
profiles of primary tumours and metastatic lesions are 
important when determining treatment strategies [16–
25]. However, to the best of our knowledge, no study 
has evaluated the clinical outcomes of patients with 
ovarian metastases from CRCs according to their BRAF 
(v-Raf murine sarcoma viral oncogene homolog B) or 
KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog) mutation profiles and status of microsatellite 
instability (MSI).
In this study, we first established the clinical 
prevalence of ovarian metastases from CRC from a 
cohort of 666 patients. Next, we analysed the clinical 
outcomes and treatment strategies, according to the 
mutational profiles of the CRCs. Finally, we evaluated 
the clinicopathologic features of women with ovarian 
metastases from CRC and attempted to determine the 
efficacy of oophorectomy in such cases.
RESULTS
Clinicopathologic features of ovarian metastases 
in women with CRC
We first evaluated the clinical prevalence of 
ovarian metastases from CRCs in 296 female patients 
in our cohort (Figure 1). These cases were categorised 
into three subsets: those with ovarian metastases (n = 19, 
6.4%), those with extra-ovarian metastases only (n = 96, 
32.4%) and those without recurrence or metastasis (n = 
181, 61.1%) (Table 1). Patients who developed ovarian 
metastases were younger than those who developed 
extra-ovarian metastases only (P < 0.0001) and had a 
median age of 51 years (range, 34–80) upon diagnosis 
of the first ovarian metastasis. Nine of the 19 women 
(47.4%) with ovarian metastases were diagnosed at ages 
younger than 50 years. With respect to the location of the 
primary colorectal tumours, 18 (94.7%) of the patients 
with ovarian metastases showed the presence of tumours 
in the colon and only 1 case showed a primary rectal 
tumour.
Genetic profiles of patients with CRCs who had 
ovarian metastases
As shown in Table 1, the KRAS mutation in 
primary tumour was equal in frequency of occurrence 
among the subsets of patients with CRC and affected 5 
of 19 patients (26.3%) with ovarian metastases, 35 of 96 
patients (36.5%) with extra-ovarian metastases only and 
66 of 181 patients (36.5%) without any recurrence or 
metastases. In the analysis of the BRAF exon 15 mutation 
in primary tumour site, 23 of the 296 female patients 
with CRC (7.8%) showed the presence of the BRAF 
mutation and all of them carried the V600E mutation. The 
BRAF V600E mutation had a non-significant tendency 
to be more frequent in patients with ovarian metastases 
(3 of 19, 15.8%) than in those with either extra-ovarian 
metastases only (6 of 96, 6.3%), or without any recurrence 
or metastasis (14 of 181, 7.7%). The MSI phenotype was 
negative in all patients with ovarian metastases but was 
observed to be equal between those with extra-ovarian 
metastases only (6 of 96, 6.3%) and those without any 
recurrence or metastasis (15 of 181, 8.3%).
Clinical outcomes of women with CRC
The median follow-up period of the 296 women 
with CRC was 30 months (range, 0–108). The outcomes 
of these patients according to their age, primary tumour 
location, histology and MSI status are summarised in 
Supplementary Figure 1. The 5-year OS rates were 100%, 
79.3%, 76.0% and 17.6% for women with CRCs at Union 
for International Cancer Control (UICC) stages I, II, III 
and IV, respectively (P < 0.0001, Figure 2A), and 24.7%, 
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34.5% and 91.3% for those with ovarian metastases, extra-
ovarian metastases only and no recurrence or metastasis, 
respectively (P < 0.0001, Figure 2B). The 3-year OS 
rates differed significantly among those with the BRAF 
V600E mutation, KRAS mutations and wild-type genes 
(43.6%, 86.5% and 73.3%, respectively; P < 0.0001, 
Figure 2C). Among the 115 women who had synchronous 
or metachronous metastases of CRC (76 patients were 
at stage IV at diagnosis and 39 patients experienced 
recurrences after curative surgery), the median survival 
times after initial treatment to progression to stage IV or 
recurrence were 21 months [95% confidence interval (CI), 
1–22 months] in patients with the BRAF mutation and 
36 months (95% CI, 26–42 months) in those without the 
BRAF mutation (BRAF wild type) (P = 0.0014, Figure 2D).
Table 2 shows the univariate and multivariate 
analyses of OS rates. In the univariate and multivariate 
analysis, the UICC stage, histology and the status of 
Table 1: Characteristics of patients with and without ovarian metastasis
Demographics
Total With ovarian metastasis
With 
extraovarian 
metastases only
No recurrence 
nor metastasis
P value(n = 296) (n = 19) (n = 96) (n = 181)
Age over 65 years 160 (54.1) 2 (10.5) 50 (52.1) 108 (59.7) 0.0009a
65 years or less 136 (45.9) 17 (89.5) 46 (47.9) 73 (40.3) 0.0002b
Location of 
primary tumour right colon 120 (40.5) 9 (47.4) 33 (34.4) 78 (43.1) 0.0284
c
left colon 111 (37.5) 9 (47.4) 35 (36.5) 67 (37.0) 0.0397d
rectum 65 (22.0) 1 (5.3) 28 (29.2) 36 (19.9)
UICC stage I 67 (22.6) 0 (0.0) 3 (3.1) 64 (35.4) 0.416a
II 69 (23.3) 0 (0.0) 8 (8.3) 60 (33.2) < 0.0001b
III 84 (28.4) 4 (21.1) 24 (25.0) 57 (31.5)
IV 76 (25.7) 15 (79.0) 61 (63.5) 0 (0.0)
T factor T0–T3 233 (79.3) 9 (52.9) 54 (56.3) 170 (93.9) 0.801a
T4 61 (20.8) 8 (47.1) 42 (43.8) 11 (6.1) < 0.0001b
Tx 2 2 0 0
Histology well or mod 270 (91.2) 17 (89.5) 81 (84.4) 172 (95.0) 0.567a
poor or muc 26 (8.8) 2 (10.5) 15 (15.6) 9 (5.0) 0.014b
KRAS/BRAF 
mutation status in 
primary lesions 
KRAS-mt 106 (35.8) 5 (26.3) 35 (36.5) 66 (36.5) 0.314a
BRAF-mt 23 (7.8) 3 (15.8) 6 (6.3) 14 (7.7) 0.662b
Wild-type of the 
both genes 167 (56.4) 11 (57.9) 55 (57.3) 101 (55.8)
MSI status in 
primary lesions
MSI 21 (7.1) 0 (0.0) 6 (6.3) 15 (8.3) 0.263a
Non-MSI 275 (92.9) 19 (100.0) 90 (93.8) 166 (91.7) 0.378b
*well or mod; well or moderately differentiated adenocarcinoma, poor or muc; poorly differentiated or mucinous 
adenocarcinoma, MSI; microsatellite instability, aP value; calculated by chi-square test between ovarian metastasis group 
and extraovarian metastasis only group, bP value; calculated by chi-square test among ovarian metastasis group, extraovarian 
metastasis only group and no recurrence nor metastasis group, cP value; calculated by chi-square test of colon (including right 
and left colon) versus rectum between ovarian metastasis group and extraovarian metastasis only group, dP value; calculated 
by chi-square test of colon (including right and left colon) versus rectum among ovarian metastasis group, extraovarian 
metastasis only group and no recurrence nor metastasis group.
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ovarian metastasis and BRAF or KRAS mutations were 
significantly associated with the OS.
Mutation status concordance between primary 
colorectal tumour lesions and ovarian metastatic 
sites
Supplementary Table 1 presents the analysis of the 
clinicopathological factors, including the mutation status 
concordance of 19 women with ovarian metastasis from 
CRC who underwent hemi-oophorectomy (n = 8) and 
bilateral oophorectomy (n = 11). Of these 19 patients, 
the mutation spectrum of 18 patients could be analysed in 
their primary tumour lesions and corresponding ovarian 
metastatic sites. All 18 patients analyzed presented the 
BRAF mutation and MSI status concordance. In contrast, 
a disconcordance of the KARS mutation status was 
determined in 16.7% (3 of 18) of paired primary tumours 
and corresponding ovarian metastases. In addition, 
the 2 cases with KRAS wild type in primary tumours 
demonstrated KRAS G12S or G12V in the corresponding 
ovarian metastasis. The remaining case presented 
KRAS G12D in the primary tumour but none in ovarian 
metastasis.
Responses to preoperative chemotherapy in 
patients with CRCs who had ovarian metastases
The response to preoperative chemotherapy 
was evaluated in 10 of 19 patients with ovarian and 
extra-ovarian metastases. Nearly all patients with 
ovarian metastases were unresponsive to preoperative 
chemotherapy, but those with extra-ovarian metastases 
had good responses (Figure 3A and Supplementary 
Table 2). Of the 10 patients who received preoperative 
chemotherapy, 9 had measurable metastases to extra-
ovarian sites and to the ovaries; 5 of these 9 patients (56%) 
achieved partial response (PR) or complete response 
(CR) at the extra-ovarian sites. On the other hand, only 
1 of the 9 patients (11%) achieved stable disease (SD) at 
ovarian sites, whereas 8 of the 9 patients (89%) exhibited 
progressive disease (PD).
Survival and timing of oophorectomy for 
patients with CRCs who had ovarian metastases
In the patients with CRCs who had ovarian 
metastases, the ovarian-specific median survival 
time (MST) was 25 months (95% CI, 15–40 months) 
(Supplementary Figure 2A), whereas the median ovarian-
specific progression-free survival (PFS) was 5 months 
(95% CI, 3–12 months) (Supplementary Figure 2B).
Because women with CRCs who had the BRAF 
V600E mutation had a worse prognosis than those with 
the BRAF wild-type (KRAS mutation and the wild type 
of both genes) gene (Figure 2A and 2B), we established 
the clinical features of the 115 women with metachronous 
or synchronous metastases, including ovarian metastases 
from CRC, according to the BRAF mutation status. In 
the 96 patients with only extra-ovarian metastases, the 
MST after initial treatment to progression to stage IV or 
recurrence was 13 months (95% CI, 1–22 months) for 
patients with the BRAF mutation and 34 months (95% CI, 
22–58 months) for patients without the BRAF mutation 
(P = 0.0033, Figure 4A).
Of 19 patients with ovarian metastases, 15 were 
diagnosed at stage IV and 4 developed recurrences after 
undergoing curative resections of primary colorectal 
Figure 1: The STROBE diagram of the patient cohort.
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tumours. Of 4 patients who developed metachronous 
ovarian metastases, 2 had the BRAF V600E mutation, 1 
had the KRAS mutation and 1 had the wild types of both 
genes in the primary tumour (the patients who had the wild 
types of both genes in the primary tumour demonstrated 
the KRAS mutation in the ovarian metastasis). The OS after 
initial treatments for recurrences was 22 and 24 months, 
respectively, in 2 patients with BRAF mutants, 50 months 
in 1 patient with the KRAS mutation and 50 months in 1 
patient with wild types of both genes in the primary tumour 
(50 months in the 2 patients with the KRAS mutation in the 
ovarian metastases). In patients with ovarian metastases, 
the MSTs after initial treatments to progression to stage 
IV or recurrence were 22 (95% CI: 21–25 months) and 38 
months (95% CI: 24–42 months) in those with and without 
the BRAF mutation, respectively (P = 0.0398; Figure 4B). 
The MST of the ovarian-specific OS was 13 (95% CI: 
7–16 months) and 27 months (95% CI: 16–41 months) in 
patients with the BRAF V600E mutation and the BRAF 
wild-type gene, respectively (P = 0.0091; Figure 4C).
As expected, the success rates of the first 
oophorectomies significantly affected survivals. Those 
Table 2: Univariate and Multivariate analysis for survival
Clinicopathologic Factor
OS
Univariate Multivariate
RR (95% CI) P value RR (95% CI) P value
Age 0.8626 0.0364
> 65 (vs < 65) 0.96 (0.60–1.53) 1.74 (1.04–2.94)
Location of primary tumour 0.8633 0.9198
right colon (vs left colon and rectum) 0.96 (0.59–1.53) 1.03 (0.58–1.81)
UICC stage < 0.0001 0.0006
II (vs I) 1.659 (3.07–∞) 0.0017 9.42e+8 (1.52–∞) 0.0188
III (vs I) 2.40e+9 (4.70–∞) 0.0001 1.18e+9 (1.97–∞) 0.0083
IV (vs I) 1.19e+10 (1.48e+6–∞) <.0001 2.63e+9 (4.30–∞) 0.0003
III (vs II) 1.45 (0.66–3.40) 0.3614 1.25 (0.54–3.10) 0.6081
IV (vs II) 7.16 (3.66–15.7) < 0.0001 2.79 (1.22–7.12) 0.0141
IV (vs III) 4.94 (2.87–8.92) < 0.0001 2.23 (1.23–4.29) 0.0080 
Histology 0.0004 0.0145
poor or muc (vs well or mod) 3.53 (1.84–6.28) 2.50 (1.21–4.82)
Status of ovarian metastasis < 0.0001 < 0. 0001
with ovarian metastasis (vs no recurrence nor 
metastasis) 15.8 (7.11–37.3) < 0.0001 7.79 (2.80–22.4) 0.0001
with extraovarian metastases only (vs no 
recurrence nor metastasis) 11.1 (5.70–24.2) < 0.0001 6.79 (2.94–16.7) < 0.0001
with ovarian metastasis (with extraovarian 
metastases only) 1.42 (0.78–2.46) 0.2371 1.15 (0.58–2.18) 0.6841
MSI status in primary lesions 0.8119 0.3993
MSI (vs non-MSI) 1.12 (0.39–2.51) 1.56 (0.51–3.84)
BRAF/KRAS mutational status in primary lesions 0.0130 0.0087
BRAF-mt (vs wild-type of both genes) 2.46 (1.16–4.74) 0.0212 2.37 (1.00–9.61) 0.0030 
KRAS-mt (vs wild-type of both genes) 0.70 (0.40–1.19) 0.1923 0.58 (0.30–1.06) 0.0782 
BRAF-mt (vs KRAS-mt) 3.50 (1.56–7.40) 0.0034 4.09 (1.65–9.61) 0.0030 
*well or mod; well or moderately differentiated adenocarcinoma, poor or muc; poorly differentiated or mucinous 
adenocarcinoma, MSI; microsatellite instability.
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with a curability rate of R0 or R1 had an MST of the 
ovarian-specific OS of 43 months (95% CI, 16 months–
not calculated), whereas those with R2 disease had an 
MST of 16 months (95% CI, 13–38 months) (P = 0.0058, 
Supplementary Figure 2C). In contrast, no relationship 
was observed between the ovarian-specific OS from the 
first oophorectomy and the interval from the diagnosis of 
ovarian metastasis to oophorectomy (ρ = −0.073, Figure 
4D). Similarly, the ovarian-specific OS after the initial 
oophorectomies exhibited a weakly positive, but non-
significant, association with the reduction rates of extra-
ovarian sites (ρ = 0.477, Figure 4E).
Notably, the additional knowledge gained from the 
post-oophorectomy pathologic examinations suggests 
that the possibility of another occult cancer of the ovary 
should be approached with caution. Of the 11 cases that 
underwent bilateral oophorectomies, 9 appeared to have 
either unilateral or no metastases at the time of clinical 
and surgical diagnoses; however, 5 of these 9 cases (56%) 
were eventually diagnosed with bilateral metastases.
DISCUSSION
The growth of ovarian tumours can cause serious 
clinical symptoms, such as abdominal pain, a heavy 
feeling in the abdomen, constipation, frequent urination 
and anorexia. Systemic therapy does not usually improve 
these symptoms, even with the availability of new 
molecular-targeted agents or cytotoxic chemotherapy 
regimens [13–15]. In this retrospective study, we 
determined the clinical prevalence, outcomes and 
appropriate treatment strategies in a large cohort of 
patients with ovarian metastases from CRCs, according 
to their somatic mutation profiles.
Previous studies have demonstrated that female 
patients with CRC who developed ovarian metastases 
were younger, and more than 80% of the primary tumours 
were in the colon [9, 15]. Consistent with previous 
reports, in our study, 18 (95%) of the 19 primary tumours 
from patients with ovarian metastases were in the colon. 
This trend strongly suggested that ovarian metastases 
Figure 2: Clinical outcomes of 296 women with CRCs. Kaplan–Meier estimates according to (A) UICC stage; (B) status of ovarian 
and other metastases; and (C) the BRAF or KRAS mutation status, in 296 women with CRCs. (D) Kaplan–Meier estimates according to 
the BRAF or KRAS mutation status in 115 women with CRCs who had metachronous or synchronous metastases. P values were calculated 
using the log-rank test. CRC, colorectal cancer; UICC, Union for International Cancer Control; Wild type, wild type of both KRAS and 
BRAF genes; KRAS-mt, KRAS mutations; BRAF-mt, BRAF V600E mutation; BRAF-wt, BRAF wild type (KRAS mutations and wild type 
of both genes).
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from CRCs spread via dissemination rather than by 
haematogenous or lymphogenous routes. However, 
in accordance with a previous study [9], there was no 
association between the depths of the invasion (T factor) 
and the frequency of ovarian metastases.
While the concordant BRAF mutation and the 
MSI status were observed in 100% (18 of 18) paired 
samples of primary colorectal tumours and corresponding 
ovarian metastases, the KRAS mutation concordance 
was observed in 83.3% (15 of 18) of them. Baas et al. 
demonstrated the overall concordance rate of 93% 
(range, 76%–100%) for the KRAS mutation status 
between primary colorectal tumours and corresponding 
metastatic sites by summarising 21 studies that reported 
concordance of the KRAS mutation status [26]. The two 
cases who showed the primary tumours with KRAS wild 
type and the corresponding ovarian metastasis with KRAS 
G12S or G12V did not received any anti-EGFR antibody 
before oophorectomies. This strongly suggests that such 
disconcordance does not result from newly acquired 
mutations obtained from chemotherapies with anti-EGFR 
antibody.
The results of this study revealed that the responses 
of patients with ovarian metastases were worse than those 
with extra-ovarian metastases (0% vs. 56%). Similarly, 
among 20 evaluable patients, Goere et al. reported that 
responses to cytotoxic chemotherapy were worse in 
patients with ovarian metastasis than in those with extra-
ovarian lesions (0% vs. 35%) [13]. Among 33 patients 
who did not undergo oophorectomies, Lee et al. reported 
that responses to chemotherapy in those with ovarian 
and extra-ovarian metastases were 18.2% and 33.3%, 
respectively [15].
In contrast to the poor responses to chemotherapy 
in CRC patients with ovarian metastases, there was 
an ovarian-specific survival benefit in patients who 
underwent oophorectomies, with ovarian-specific 
MSTs of 43 and 16 months for patients who underwent 
complete resections (R0 or 1) and palliative debulking 
(R2), respectively. Notably, even palliative debulking 
Figure 3: Responses to systemic chemotherapy and outcomes after undergoing oophorectomy. (A) Responses to systemic 
chemotherapy in 9 women with CRCs that had metastasised to the ovary or to other organs, or both; (B) Ovarian-specific PFS; and (C) OS 
after oophorectomy. Numbers indicate the number of patients (Supplementary Table 1) who were censored (i.e., alive at the time of data 
extraction). CRC, colorectal cancer; PFS, progression-free survival; OS, overall survival; Wild type, wild type of both KRAS and BRAF 
genes in the ovarian metastatic lesions; KRAS-mt, KRAS mutations in the ovarian metastatic lesions; BRAF-mt, BRAF V600E mutation in 
the ovarian metastatic lesions.
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prolonged the durations of the absence of either serious 
abdominal symptoms or anorexia due to ovarian 
metastases. We did not analyse the patients who did not 
undergo oophorectomies; however, in an earlier study, 
Lee et al. analysed 130 patients with ovarian metastases 
from CRCs and found that the MSTs after the diagnoses 
of ovarian metastasis were 20.8 months in 83 patients who 
underwent oophorectomy and 10.9 months in 47 patients 
who did not [15]. Therefore, our study and previous 
reports collectively suggested that although oophorectomy 
remains an uncommon perioperative treatment procedure, 
it is a promising and feasible management option for 
patients with CRCs who have ovarian metastases. Thus, 
ovarian metastasis is rather close to dissemination than 
a metastasis, oophorectomies play an important role for 
local control for the disease. Surgery will have some 
benefit for limited peritoneal dissemination in patients 
with CRC. Conversely, chemotherapy will have limited 
benefit for peritoneal dissemination.
Based on recent studies that showed worse 
prognoses in patients with advanced CRCs who harboured 
the BRAF V600E mutation than those who did not [16–
19, 22, 23, 27], we analysed the genetic backgrounds and 
prognoses of female patients with CRCs in our cohort. 
Expectedly, patients with the BRAF V600E mutation 
demonstrated the worst OS among all female patients 
with different stages of CRC. This trend was also observed 
for the OS from initial treatment to progression to stage 
IV or recurrence and the ovarian-specific OS among 
female patients with CRC who had ovarian metastases 
as well as among those with extra-ovarian metastases 
only. Furthermore, 2 of 4 patients who developed ovarian 
metastases after undergoing curative resections of 
primary tumours presented the BRAF V600E mutation 
in primary tumours. Randomised phase III trials on first-
line chemotherapy demonstrated that the OS in patients 
with the BRAF mutation ranged between 9 and 15 months 
[18, 22, 28, 29]. In this study, the MST after the initial 
treatment to stage IV or recurrence was 13 months in 
BRAF-mutant patients with CRC who had extra-ovarian 
metastases only; however, the MST after the initial 
treatment to stage IV or recurrence reached 22 months in 
BRAF-mutant patients with ovarian metastases.
As our study and previous studies demonstrated [13–
15], resistance of ovarian metastases to chemotherapy was 
a common feature of ovarian metastases from CRC. Indeed, 
although patients with ovarian metastases had relatively 
the higher proportion for BRAF mutation compared with 
patients without ovarian metastases, patients with BRAF 
mutation had the poor survival irrespective of type of 
metastases. Thus BRAF/KRAS mutation or MSI status could 
not explain the reason why chemotherapy gives benefit so 
small to ovarian metastasis even though it has objective 
response to extra-ovarian metastasis.
Of 19 patients, the BRAF mutation was observed 
in 3 patients with variable duration time (0, 5.5 and 12.0 
months) to initial oophorectomy from the diagnosis 
of ovarian metastasis and survival times after initial 
oophorectomy was relatively shorter than those observed in 
patients with BRAF wild-type (Figure 4D). In contrast to the 
survival time, responses to systemic chemotherapy in extra-
ovarian metastatic sites observed in 2 BRAF-mutant patients 
(response rates, 19% and 50%) were average; however, 
oophorectomy-specific OSs were relatively shorter in them 
than in patients with BRAF wild-type (Figure 4E). From 
these results, it can be inferred that colorectal tumours with 
the BRAF mutation can shrink visibly but the PFS was 
shorter during systemic chemotherapy.
This study had several limitations: retrospective 
design, failure to include patients with ovarian metastases 
who did not undergo oophorectomy and a single-centre 
cohort. However, this study confirmed several essential 
findings regarding ovarian metastases of CRC. First, 
in corroboration with previous reports, the clinical 
prevalence of ovarian metastases from CRC was 
approximately 7%. Second, women with advanced CRCs 
with BRAF mutations demonstrated poor prognoses 
despite the status of ovarian metastasis, and the occurrence 
of the BRAF mutation was higher in female patients with 
CRCs who had ovarian metastases than those who did not. 
Third, ovarian metastases from CRCs did not respond to 
any systemic chemotherapy despite responses from other 
metastatic sites. Therefore, irrespective of their somatic 
mutation profiles, ovarian metastatectomy at the time of 
achieving the disease control at extra-ovarian metastases 
will enhance the outcome of women with colorectal 
ovarian metastases.
MATERIALS AND METHODS
Patients
We retrospectively analysed a cohort of 666 
consecutive patients with CRC who underwent surgical 
resections at the Okayama University Hospital from 
January 2007 to September 2015. This cohort included 
296 female patients; 20 of these were suspected to have 
ovarian metastases from CRCs and had undergone one or 
two oophorectomy procedures. In our department, all such 
patients who were suspected to have ovarian metastases 
from CRC, based on their radiologic evaluations, are 
eligible for oophorectomy. Therefore, in this study, we could 
not include patients with ovarian metastases who did not 
undergo oophorectomy. After careful examinations of the 
surgical and pathologic records and images, we excluded 
one patient who underwent oophorectomy for a direct 
ovarian invasion from the peritoneal metastasis of primary 
CRC. Finally, we analysed a cohort of 19 patients with 
CRCs who underwent unilateral or bilateral oophorectomies 
for ovarian metastases from CRC (Figure 1).
All patients underwent bilateral or unilateral 
oophorectomies via transabdominal laparotomy, with 
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or without the resection of primary CRC or other extra-
ovarian metastases and received chemotherapeutic 
regimens, including modified FOLFOX6 (folinic acid, 
fluorouracil and oxaliplatin), FOLFIRI (folinic acid, 
fluorouracil and irinotecan), capecitabine, CPT-11 
(irinotecan, camptosar and camptothecin-11), with or 
without bevacizumab, cetuximab or panitumumab, either 
before or after surgery, at the discretion of the surgeon or 
the preference of the patient.
OS was calculated from the date of initiation of 
treatment for a primary tumour (i.e., via surgical resection 
or systemic chemotherapy) to the date of death or last 
follow-up (for censored patients). Ovarian-specific OS 
was calculated from the date of the first oophorectomy to 
the date of death or last follow-up. Ovarian-specific PFS 
was calculated from the date of the first oophorectomy 
to the date of the ﬁrst documentation of local, regional, 
or distant relapse or the appearance of a second primary 
lesion, as determined by routine computed tomography 
scans, magnetic resonance imaging scans, or both, 
performed every 2–3 months.
Response criteria were defined according to the 
Response Evaluation Criteria in Solid Tumors (RECIST) 
guidelines, version 1.1 [30], as follows: CR, disappearance 
of all target lesions; PR, a ≥ 30% decrease in the sum of 
the target lesion diameters relative to the sum of baseline 
diameters; PD, a ≥ 20% increase in the sum of the target lesion 
diameters relative to the smallest sum of the preoperative 
tumour sites and SD, neither sufficient shrinkage of lesions 
to qualify for PR nor sufficient increase to qualify for PD. 
Figure 4: Clinical features of the female patients with ovarian metastases from CRC. Kaplan–Meier estimates of the OS 
after initial treatment to progression to stage IV or recurrence for (A) 96 women with CRCs who had extra-ovarian metastases only, and 
(B) 19 women with ovarian metastases according to their BRAF mutation status. (C) Kaplan–Meier curves of the ovarian-specific OS for 
19 women with ovarian metastases, according to their BRAF mutation status. MST denotes the median duration of the OS after initial 
treatment to progression to stage IV or recurrence and ovarian-specific OS. P values were calculated using the log-rank test. (D) The 
relationship between the ovarian-specific OS and the interval between the diagnosis of ovarian metastasis and the initial oophorectomy. (E) 
The relationship between the ovarian-specific OS and the rates of reduction of extra-ovarian metastases in 9 women treated with systemic 
chemotherapy. Among the 19 patients with ovarian metastases, 10 were treated with chemotherapy before oophorectomy; of these, 9 (90%) 
had measurable metastases to the ovaries and extra-ovarian sites. ρ denotes the Spearman’s rank correlation coefficient. Red circles denote 
patients with the BRAF V600E mutation in the ovarian metastatic lesions. Yellow squares denote patients with KRAS mutations in the 
ovarian metastatic lesions. CRC, colorectal cancer; OS, overall survival; MST, median survival time; BRAF-mt, BRAF V600E mutation; 
BRAF-wt, BRAF wild type (KRAS mutations and wild type of the both genes).
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Pathology reports for all patients were reviewed by at least 
two pathologists. Institutional review board approval was 
granted by the ethics committee of the Okayama University, 
and all patients provided written informed consents for the 
use of their body tissues for research.
The detection of BRAF exon 15 and KRAS exon 
2 mutations
To identify mutations in BRAF exon 15, including 
in codon 600, and in KRAS exon 2 in each case, Sanger 
sequencing was performed on purified DNA isolated from 
formalin-fixed, paraffin-embedded, or fresh-frozen tissues 
from the primary tumours and corresponding ovarian 
metastases. The specific primer sequences for BRAF exon 
15 and KRAS exon 2, and the polymerase chain reaction 
(PCR) conditions used here were described previously 
[31]. The PCR products were purified using QIAquick 
PCR purification kit (Qiagen, Venlo, Netherlands), 
and were directly sequenced using an ABI PRISM® 
3100-Avantä Genetic Analyzer (Applied Biosystems, 
Foster City, CA, USA). Examples of BRAF and KRAS 
mutations are shown in Supplementary Figure 3.
Microsatellite instability analysis
All primary CRC and ovarian metastatic tissues 
were subjected to an MSI status analysis using four-
mononucleotide repeat loci (BAT26, NR21, NR27 and 
CAT25), as described previously, in part [32]. Tumours 
that exhibited MSI in at least one mononucleotide repeat 
marker were classified as having MSI phenotypes, 
whereas those without MSI in any marker were classified 
as non-MSI phenotypes. An example of the MSI analysis 
is shown in Supplementary Figure 1.
Statistical analyses
Statistical analyses were performed using JMP 
software version 10.0.2 (SAS Institute, Inc., Cary, NC, 
USA). Categorical variables were compared using the Chi-
square test. Ovarian-specific OS and PFS were estimated 
by univariate analyses using the Kaplan–Meier method. 
Cox proportional hazard regression method was used to 
perform univariate and multivariate analyses of OS. The 
regression model included clinicopathologic factors, such 
as age; primary tumour location; stage per the UICC 
guidelines; histological and ovarian metastasis status 
and somatic mutation profiles, such as BRAF or KRAS 
mutations and MSI status. Spearman’s rank correlation 
coefficient (ρ) was used to analyse the relationship 
between ovarian-specific OS and the variables of the 
first oophorectomy, i.e. between the time from diagnosis 
of ovarian metastasis to oophorectomy, and between 
oophorectomy-specific OS and the rate of decrease in the 
number of extra-ovarian sites during chemotherapy. All 
reported P values were calculated using two-sided tests and 
values of < 0.05 were considered statistically significant.
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